key: cord-0819017-bz2bt4gx
authors: Thell, R.; Zimmermann, J.; Szell, M.; Tomez, S.; Eisenburger, P.; Kreil, A.; Haugk, M.; Spiel, A.; Blaschke, A.; Klicpera, A.; Janata, O.; Krugluger, W.; Sebesta, C.; Herkner, H.; Laky, B.
title: Standard blood laboratory results in SARS-CoV-19 positive patients: do they show a typical pattern?
date: 2020-10-27
journal: nan
DOI: 10.1101/2020.10.23.20217844
sha: 1a9e6e9dd8fdd19e2788a589ec85d429c6a19fab
doc_id: 819017
cord_uid: bz2bt4gx

Background Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is current pandemic disease. Acute polymerase-chain reaction is the gold standard test for this disease, is not available everywhere. Standard blood laboratory parameters may have diagnostic potential. Methods We evaluated standard blood laboratory parameters of 655 COVID-19 patients suspected to be infected with SARS-CoV-2, who underwent PCR testing in one of five hospitals in Vienna, Austria. Additionally, clinical characteristics and 28-day outcome were obtained from medical records. We compared standard blood laboratory parameters, clinical characteristics, and outcomes between positive and negative PCR-tested patients and evaluated the ability of those parameters to distinguish between groups. Results Of the 590 study patients including 276 females and 314 males, aged between 20 and 100 years, 208 were tested positive by means of PCR. Patients with positive compared to negative PCR-tests had significantly lower levels of leukocytes, basophils, eosinophils, monocytes, and thrombocytes; while significantly higher levels were detected with hemoglobin, C-reactive-protein (CRP), neutrophil-to-lymphocyte ratio (NLR), activated-partial-thromboplastin-time (aPTT), creatine-kinase (CK), lactatedehydrogenase (LDH), alanine-aminotransferase (ALT), aspartate-aminotransferase (AST), and lipase. Our multivariate model correctly classified 83.9% of cases with a sensitivity of 78.4%, specificity of 87.3%, positive predictive value of 79.5%, and negative predictive value of 86.6%. Decreasing leucocytes and eosinophils and increasing hemoglobin and CRP were significantly associated with an increased likelihood of being COVID-19 positive tested. Conclusions Our findings suggest that especially leucocytes, eosinophils, hemoglobin, and CRP are helpful to distinguish between COVID-19 positive and negative tested patients and that a certain blood pattern is able to predict PCR-results.

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

C-reactive-protein (CRP), neutrophil-to-lymphocyte ratio (NLR), activated-partial-66 thromboplastin-time (aPTT), creatine-kinase (CK), lactate-dehydrogenase (LDH), alanine-67 aminotransferase (ALT), aspartate-aminotransferase (AST), and lipase. Our multivariate model 68 correctly classified 83.9% of cases with a sensitivity of 78.4%, specificity of 87.3%, positive 69 predictive value of 79.5%, and negative predictive value of 86.6%. Decreasing leucocytes and 70 eosinophils and increasing hemoglobin and CRP were significantly associated with an increased 71 likelihood of being COVID-19 positive tested. 72

Conclusions. Our findings suggest that especially leucocytes, eosinophils, hemoglobin, and 73 CRP are helpful to distinguish between COVID-19 positive and negative tested patients and that 74 a certain blood pattern is able to predict . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 It soon became apparent that the available test capacities for PCR testing were far from 89 sufficient, and a feverish search for alternative and simpler detection methods began. To date, 90 point-of-care PCR testing is still not available everywhere. Testing that takes a long time can 91 make up for significant additional efforts of organisation of patient cohorts in hospitals. 92

The clinical appearance of the disease is broadly reported. [3] Signs and symptoms may include 93 fever and cough most commonly, dyspnea, rarely diarrhea, anosmia, or ageusia and others, at the 94 beginning or during the course of the disease. higher numbers of D-Dimer, C-reactive protein (CRP), and procalcitonin in patients to be 99 admitted to intensive care levels. In a retrospective report of 138 admitted patients, lymphopenia 100 occurred in 70%, a prolonged prothrombin time in 58%, and an elevated lactate dehydrogenase 101 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 27, 2020. Therefore, the overall aim of this study was to evaluate standard blood laboratory parameters and 119 clinical characteristics in a large number of COVID-19 suspicious patients, who underwent PCR 120 testing. The specific aim was to determine whether standard blood laboratory parameters are able 121 to identify positive COVID-19 patients from a large COVID-19 suspected cohort. 122

Data were obtained from an electronical data base of the Vienna Health Care Association 126 (Wiener Gesundheitsverbund), which stores all medical records of patients treated in its hospitals 127 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 27, 2020. were divided into a COVID-19 positive or negative group. Patients without reported standard 138 blood laboratory reports, medical history, or outcome documentation at day 28 after consultation 139 were not included. 140

As standard blood laboratory testing was performed according to the clinical care needs of the 141 patients, not all parameters were available for all patients. Parameters available from less than 20 142 patients in the positive or negative group were not analysed. Routine blood tests generally 143 included full blood count, blood chemistry, electrolytes, liver function parameters, renal and 144 myocardial function parameters as well as coagulation markers and markers of inflammation. 145

Patients' gender (female/male), age at time of PCR testing (years), coexisting diseases and 146 conditions (e.g. chronic diseases of the lung, liver, kidney; coronary artery disease, diabetes, and 147 arterial hypertension); the clinical 28-day outcome including hospital admission and discharge as 148 well as requirement of intensive care and ventilation, and death details were extracted from 149 medical records. 150 151

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.23.20217844 doi: medRxiv preprint 7 Descriptive statistics was used to describe the characteristics of patients. The distribution of the 153 data was determined by visual inspection of the histograms and the Kolmogorov Smirnov tests. 154

Normally distributed data were calculated as mean value with standard deviation (SD), otherwise 155 as median and interquartile range (IQR). 156

Continuous variables were compared between COVID-19 positive and negative patients with 157 independent t-tests (parametric) or Mann-Whitney U-tests (non-parametric). Blood parameters 158

were categorised according to normal reference ranges used in hospitals. However, since CRP 159 ranges higher than normal (cut off: 0.5mg/dL) were detected in almost all patients (COVID-19 160 positive: 99.5% and negative: 98.2%) and thus, useless to discriminate between COVID-19 161 positive and negative patients, coordinates of the receiver operating characteristic (ROC) and the 162 Youden index were used to determine another, sensitivity and specificity balanced, cut off value 163 for CRP in our cohort. Chi-square or Fisher's exact tests were applied to describe the relationship 164 between proportions of categorical variables. Correlations between the continuous parameters 165 were performed using Kendall's Tau. Since neutrophils significantly correlated with leucocytes 166 (0.859; p<0.001) and to reduce the number of predictive variables, we used the neutrophils-to-167 lymphocytes ratio (NLR) instead of neutrophils and lymphocytes. A cut-off for NLR was 168 determined using coordinates of the ROC and the Youden index (sensitivity and specificity 169 balanced). Hemoglobin was used instead of erythrocytes (0.761; p<0.001) and hematocrit (0.874; 170 p<0.001) due to significant correlations. Procalcitonin and D-Dimer were also not included due 171 to the small sample size. For further analysis between COVID-19 positive and negative patients, 172 only significant different and clinical meaningful parameters were considered. 173

Univariate and multivariate binomial logistic regression analyses were used to construct 174 prediction models using PCR results (COVID-19 positive/negative) as the dependent variable 175 and significant patients' characteristics and blood parameters as predictors (independent 176 variables). Linearity of the continuous variables regarding the logit of the dependent variable 177 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.23.20217844 doi: medRxiv preprint 8 was assessed using Box-Tidwell procedure with Bonferroni correction. None of the continuous 178 variables violated the linearity assumption. None of the parameters showed multicollinearity. 179

Percentage accuracy in classification (PAC), sensitivity, specificity, positive predictive value 180 (PPV), and negative predictive value (NPV) were estimated to assess models' performance. Area 181 under the ROC curves (AUC) were determined in order to assess the overall discriminatory 182 ability of the model and of blood parameters to distinguish between COVID-19 positive and 183 negative patients. Statistical significance was set at a p-value of <0.05 (two-sided). All data were 184 analysed with SPSS software (IMP Statistics Version 25; SPSS Inc, Chicago, IL). 185

A total of 655 patients from the four hospitals underwent PCR testing between February 27, 189 2020 and April 27, 2020. Forty-five patients were not evaluated due to missing data. Another 17 190 patients who were tested within this time period with complete data sets were excluded since 191 they were hospitalized more than one month before (n=16) or more than seven days after (n=1) 192 PCR-testing. Patients (n=3) with both eosinophilia and acute malignant disease were excluded as 193 well. 194

The median age of the 276 female (46.8%) and 314 male (53.2%) patients was 71 years (range, 195 20-100years; 60.7% of the patients were <0.001). The most common comorbidity was pre-existing arterial hypertension (58.1%), 200 followed by diabetes (25.4%), coronary heart disease (19.5%), chronic lung disease (16.9%), 201 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.23.20217844 doi: medRxiv preprint chronic kidney disease (15.8%), malignant diseases (13.6%), cerebrovascular accidents (7.5%), 202 chronic liver disease (4.2%), and human immunodeficiency virus (HIV, 0.5%). 203

A comparison between demographic characteristics and comorbidities between COVID-19 204 positive and negative tested patients showed no significant differences between the groups 205 (Table 1) . 206

Similar numbers of outpatients tested positive (11.1%) or negative (8.6%; p=0.338). There was 207 also no significant difference between COVID-19 positive compared to negative tested patients 208 regarding the number of patients requiring ICU and/or ventilation (4.0% vs. 9.3%, respectively; 209 p=0.091). Significantly more COVID-19 positive (25.5%) than negative (9.2%) tested patients 210 died before day 28 (p<0.001). Main causes of death in COVID-19-positive patients were, in 211 descending order, pneumonia (67.3%), followed by multi-organ failure (24.5%), acute cardiac 212 failure (7.6%), and acute renal failure (1.9%). 213 214

Negative Patients 216 COVID-19 positive patients had significantly lower levels of leukocytes, NLR, basophils, 217 eosinophils, monocytes, and thrombocytes; while significantly higher levels were detected with 218 hemoglobin, CRP, aPTT, CK, LDH, ALT, AST, and lipase compared to COVID-19 negative 219 patients. Similar levels were detected regarding procalcitonin, albumin, glucose, potassium, total 220 bilirubin, GGT, creatinine, and BUN between the groups (Supplement Table 1 ). Parameters with 221 significant differences are presented in Table 2 . 222

After dichotomizing blood laboratory parameters, similar significances were detected (Table 2) ; 223 while binary comparisons of aPTT (normal+high (≥21sec): 97.9% positive vs. 97.6% negative) 224 and total bilirubin (normal+high (≥0.3mg/dL): 93.6% positive vs. 89.6% negative) showed no 225 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.23.20217844 doi: medRxiv preprint significant differences between positive and negative tested patients (p=0.885 and p=0.132, 226 respectively). 227 228

Univariate logistic regression analysis with COVID-19 positive tested patients as the dependent variable 230 revealed that the majority of blood parameters including the dichotomized levels were associated with a 231 positive COVID-19 diagnosis (Table 3) . Comorbidities due to their low discrimination ability and 232 parameters without significant associations were not included in further multivariate analyses 233 (Supplement Table 2 ). 234

The multivariate logistic regression model was statistically significant (Chi-square (14) = 119.2; p<0.001) 235 and explained 62.8% (Nagelkerke R 2 ) of the variance in COVID-19 positive tested patients and correctly 236 classified 83.9% of cases. Sensitivity was 78.4%, specificity was 87.3%, positive predictive value was 237 79.5%, and negative predictive value was 86.6%. Of the 14 predictors, four were statistically significant 238 including leucocytes, eosinophils, hemoglobin, and CRP (Table 3) . Decreasing leucocytes and 239 eosinophils as well as increasing hemoglobin and CRP were associated with an increased likelihood of 240

being COVID-19 positive tested. AUC, as a measure of the overall discriminatory ability of the model, 241 and the model's best blood parameters combined are presented as ROC curves in Figure 1 . 242 243

Diagnostic performance of those four dichotomized blood parameters, which were significant at the 245 multivariate logistic regression as well as those, which were significant at the univariate analysis, were 246 evaluated regarding their ability as single parameter to distinguish between COVID-19 positive from 247 negative tested patients (Table 4 ). Each single parameter showed either a high sensitivity (leucocytes, 248 eosinophils, CRP, monocytes, platelets), a high specificity (NLR, CK, ALT, lipase), or a sensitivity and 249 specificity around 60% (hemoglobin, LDH, AST). 250 251 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.23.20217844 doi: medRxiv preprint

In this trial, we showed that the likelihood of a SARS-CoV-2 infection can be enforced through 253 standard laboratory blood findings to a high degree. Several studies including meta-analyses 254 recently focused on prediction of the severity of the disease derived from blood results. [8, 9, 16] 255 Our consideration to find a model to predict the diagnosis of SARS-CoV-2 infection with 256 standard blood parameters has been less studied. 257

To our knowledge, only three other trials comparing standard blood parameters between positive 258 and negative cases are published to date. [11, 12, 17] Similar to those studies, our study showed 259 that leucopenia, eosinopenia, elevated hemoglobin, and CRP were detected to be among the best 260 standard laboratory parameters to distinguish between COVID-19 positive from negative tested 261 patients. Accordingly, similar patterns have been detected in positive COVID-19 patients with a 262 severe compared to a mild form of the disease. [8, 9, 16] The major differences of the three 263 studies, which compared COVID-19 positive and negative patients, opposed to the reviews, 264

which reported only on positive tested patients, were documented regarding leucocytes, 265 neutrophils, and hemoglobin (Table 5) . 266

In conformity with other publications [11, 12, 17] , leucocytes were lower in COVID-19 positive 267 than negative patients at the time of PCR testing, and so were neutrophils and lymphocytes; 268 while severe compared to mild forms of COVID-19 tend to have higher leucocytes and 269 neutrophils. As opposed to our findings, which showed a low ability of NLR to discriminate 270 between positive and negative (AUC=0.561) and basically no contribution in the multivariate 271 analysis, a raised NLR, which evolved from a raised neutrophil count as well as a lowered 272 lymphocyte count, was already shown previously to be a prognostic value for endotracheal 273 intubation and mortality predictor. [13, 14] A cut-off of 4.94 was used in the publication by 274

Tatum et al. [14] ; above this value, the risk of being artificially ventilated or to die was 275 increased. Notably, 89% of those patients were African Americans. A lower cut-off (2.33) was 276 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.23.20217844 doi: medRxiv preprint established in our study, which might be because only 15% of patients had a neutrophil count 277 higher than 7.7x10 9 /L. We are however unaware of any study using NLR as a pure discriminator 278 between positive and negative COVID-19 diagnosis. 279

However, severity of illness appears to be less important regarding the other parameters, 280 especially regarding eosinophils and CRP (Table 5) . Like in other publications [12, 17] , our data 281 also showed that eosinopenia was one of the significant predictive biomarkers for COVID-19 282 with a sensitivity of 85% and a specificity of 50%. 283

Li et al. [12] and our study showed an increased hemoglobin in COVID-19 positive patients, 284 which is not in accordance with a lowered hemoglobin in patients with severe COVID-19 285 disease reported by two meta-analyses. [8, 16] In our data, the median hemoglobin was 13.5 286 g/dL, which did not much differ from Li's data. [12] In several other trials assessing the severity 287 of disease and blood patterns, hemoglobin was shown to be below normal ranges. [8, 9, 16] It can 288 only be hypothesized why our cohort presented with a comparably high level of hemoglobin. Not surprisingly, CRP was significantly elevated in all studies. [11, 12, 17] In our patients, we set 294 a new cut-off using the Youden index of 22 mg/dL, since the vast majority of patients had 295

increased CRP values. 296 Similar blood patterns were also detected regarding ALT, AST, and LDH. [8, 9, 12, 16, 17] 297 Brinati et al. included 279 patients and developed a score for SARS-Cov-2 detection with an 298 accuracy between 82% and 86%, and sensitivity between 92% and 95%.

[18] Applying our data 299 including age, gender, leucocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, 300 thrombocytes, CRP, AST, ALT, GGT, and LDH to Brinati's tool, a quite high AUC 301 (AUC=0.709, 95%CI 0.646-0.771; p<0.001), sensitivity (70.4%), specificity (71.3%), and NPV 302 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.23.20217844 doi: medRxiv preprint 13 (79.9%), but less promising PPV (59.8 %) could be obtained. However, our model including 14 303 standard laboratory blood parameters reached better diagnostic performances in all areas 304 (AUC=0.915, 95%CI 0.876-0.955); sensitivity (78.4%); specificity (87.3%), PPV (79.5%), and 305 NNP (86.6%)), although, the most prominent parameters were leucocytes, eosinophils, 306 hemoglobin, and CRP. 307

The following limitations of the study should be noted. The retrospective design with missing 308 blood parameters and no validation cohort are amongst the major limiting factors and thus, our 309 selected model may be over-fitted. Additionally, with the single time point evaluation, we were 310 not able to retrieve information regarding progression of the disease. Furthermore, cytokines, 311 especially interleukin-6, were not routinely measured, which may be better predictors, especially 312 regarding the so-called ‚COVID-19 cytokine storm', to elucidate COVID-19 positive from 313 negative patients. Another fact to consider is the heterogeneity of underlying diseases, which 314 may also contribute to variations in our findings. On the other hand, such a heterogeneity may 315 reflect reality during a pandemic situation best. Eventually, all test quality crucially depends on 316 the quality of the manual specimen acquisition. [19, 20] PCR results tend to be more positive in 317 patients with an increased viral load and with a shorter duration of the disease.

[21] 318

Generally, as laboratory equipment supply develops, more PCR point-of-care diagnostics 320 become available. It is nonetheless doubtful that -neither in the near, nor in the far future -PCR 321 will entirely replace standard laboratory testing. Therefore, the question of a blood laboratory 322 pattern, as specific as possible for COVID-19, remains relevant. Our multivariate model 323 including 14 standard blood parameters correctly classified 84% of cases with a sensitivity of 324 78% and a specificity of 87%, and therefore could be a useful model to facilitate rapid triage of 325 potential COVID-19 patients. 326 327 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 Funding 328

There was no acquisition of any funding for this trial. 329 330 Acknowledgment 331

All authors declare that they have no conflict of interest. 332 333 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.23.20217844 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10.1101/2020.10.23.20217844 doi: medRxiv preprint -. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 27, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10. 1101 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10. 1101 

From Hendra to Wuhan: what has 335 been learned in responding to emerging zoonotic viruses

Combination of RT-qPCR testing and clinical features 338 for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak

Epidemiological and clinical characteristics of 99 cases 341 of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 27, 2020. ; https://doi.org/10. 1101